Skip to main content Skip to main navigation menu Skip to site footer

Comparison of the nutritional status and lipid profile of tuberculosis patients with and without type 2 diabetes mellitus in primary health care in Bandung

  • Afiat Berbudi ,
  • Chansa Camilla ,
  • Nofri Rahmadika ,
  • Adi Imam Cahyadi ,
  • Rovina Ruslami ,

Abstract

Background: Diabetes mellitus (DM) and tuberculosis (TB) both are major global health problems. DM, primarily type 2 DM (T2DM) is often associated with obesity, hypertriglyceridemia, and high cholesterol and is a risk factor for TB. Diabetes is also associated with poor TB treatment outcomes. Since Mycobacterium tuberculosis (Mtb) relies on host nutrients, lipids, and cholesterol to survive, more knowledge about the nutritional status and lipid profile of T2DM, TB, and TB-T2DM patients is needed in order to establish novel TB management strategies for TB-T2DM patients.

Methods: Cross-sectional study was conducted to compare the nutritional status and lipid profile of TB-T2DM, TB, and T2DM only patients using data collected from several Primary Health Cares in Bandung, Indonesia. In total, 77 TB-T2DM, TB only, and T2DM only patients treated at the Primary Health Care Centers in Bandung, Indonesia, were recruited.

Results: BMI and the lipid profiles of the TB patients were significantly lower than those of T2DM patients (p<0.05). BMI and HDL levels were significantly lower in the TB-T2DM patients than those in T2DM patients (p<0.001 and p=0.04). Total cholesterol levels were significantly lower in TB compared to those in the TB-T2DM group (p=0.025).

Conclusion: All lipid profiles showed a similar pattern with the T2DM without TB having the highest lipid levels, followed by TB-T2DM and TB patients. 

References

  1. World Health Organization. Global Tuberculosis Report 2018. Geneva; 2018.
  2. World Health Organization. Global Report on Diabetes. Vol. 58. Geneva; 2016.
  3. International Diabetes Federation. IDF Diabetes Atlas. 8th ed. International Diabetes Federation, editor. Brussels, Belgium: International Diabetes Federation; 2017.
  4. Ruslami R, Aarnoutse RE, Alisjahbana B, Van Der Ven AJAM, Van Crevel R. Implications of the global increase of diabetes for tuberculosis control and patient care. Trop Med Int Heal. 2010;15(11):1289–99. Available from: 10.1111/j.1365-3156.2010.02625.x
  5. Alisjahbana B, van Crevel R, Sahiratmadja E, M den heijer, Maya A, Istriana E, et al. Diabetes mellitus is strongly associated with tuberculosis in Indonesia. Int J Tuberc Lung Dis. 2006;10(6):696–700.
  6. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics [Internet]. Vol. 9, The Lancet Infectious Diseases. 2009. p. 737–46. Available from: 10.1016/S1473-3099(09)70282-8
  7. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: A systematic review of 13 observational studies. PLoS Med. 2008;5(7):1091–101. Available from: 10.1371/journal.pmed.0050152
  8. Segura-cerda CA, López-romero W, Flores-valdez MA. Changes in Host Response to Mycobacterium tuberculosis Infection Associated With Type 2 Diabetes : Beyond Hyperglycemia. Front Cell Infect Microbiol. 2019;9(October):1–10. Available from: 10.3389/fcimb.2019.00342
  9. Tanwar P, Shivangi, (India) LSM. Cholesterol Metabolism: As a Promising Target Candidate for Tuberculosis Treatment by Nanomedicine. J Nanomater Mol Nanotechnol. 2020;2020. Available from: 10.4172/2324-8777.1000273
  10. Brzostek A, Pawelczyk J, Rumijowska-Galewicz A, Dziadek B, Dziadek J. Mycobacterium tuberculosis is able to accumulate and utilize cholesterol. J Bacteriol. 2009;191(21):6584–91. Available from: 10.1128/JB.00488-09
  11. Mali PC, Meena LS. Mini-Review Triacylglycerol: nourishing molecule in endurance of Mycobacterium tuberculosis. J Biosci. 2038;43(1):149–54. Available from: 10.1007/s12038-018-9729-6
  12. Wilburn KM, Fieweger RA, VanderVen BC. Cholesterol and fatty acids grease the wheels of Mycobacterium tuberculosis pathogenesis [Internet]. Vol. 76, Pathogens and disease. Oxford Academic; 2018. p. 21. Available from: 10.1093/femspd/fty021
  13. Jiménez-Corona ME, Cruz-Hervert LP, García-García L, Ferreyra-Reyes L, Delgado-Sánchez G, Bobadilla-Del-Valle M, et al. Association of diabetes and tuberculosis: Impact on treatment and post-treatment outcomes. Thorax. 2013;68(3):214–20. Available from: 10.1136/thoraxjnl-2012-201756
  14. Dooley KE, Tang T, Golub JE, Dorman SE, Cronin W. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg. 2009;80(4):634–9. Available from: 10.4269/ajtmh.2009.80.634
  15. Han X, Wang Q, Wang Y, Cai J, Ma Y, Zhou X, et al. The impact of diabetes on tuberculosis treatment outcomes: evidence based on a cumulative meta-analysis. Int J Diabetes Dev Ctries. 2016;36(4):490–507. Available from: 10.1007/s13410-016-0514-5
  16. Prada-Medina CA, Fukutani KF, Pavan Kumar N, Gil-Santana L, Babu S, Lichtenstein F, et al. Systems Immunology of Diabetes-Tuberculosis Comorbidity Reveals Signatures of Disease Complications. Sci Rep. 2017;7(1):1999. Available from: 10.1038/s41598-017-01767-4
  17. Nijland HMJ, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RHH, et al. Exposure to Rifampicin Is Strongly Reduced in Patients with Tuberculosis and Type 2 Diabetes. Clin Infect Dis. 2006;43(7):848–54. Available from: 10.1086/507543
  18. Vrieling F, Ronacher K, Kleynhans L, van den Akker E, Walzl G, Ottenhoff THM, et al. Patients with Concurrent Tuberculosis and Diabetes Have a Pro-Atherogenic Plasma Lipid Profile. EBioMedicine. 2018;32:192–200. Available from: https://doi.org/10.1016/j.ebiom.2018.05.011
  19. Lindarto D, Syafril S, Gatot D. The Correlation between Glycemic Characteristic and Erythrocyte Indices in Obesity. Indones Biomed J. 2016;8(3):176. Available from: https://doi.org/10.18585/inabj.v8i3.215
  20. Schwenk A, Macallan DC. Tuberculosis, malnutrition and wasting [Internet]. Current Opinion in Clinical Nutrition and Metabolic Care. 2000. Available from: 10.1097/00075197-200007000-00008
  21. Kanna KS. Effect of the Lipid Profile Differs With Tuberculosis Subject Innovation To Eliminate-a Review. Asia Pacific J Res. 2015;1(Xxi):185–90.
  22. Daniel J, Deb C, Dubey VS, Sirakova TD, Abomoelak B, Morbidoni HR, et al. Induction of a novel class of diacylglycerol acyltransferases and triacylglycerol accumulation in Mycobacterium tuberculosis as it goes into a dormancy-like state in culture. J Bacteriol. 2004;186(15):5017–30. Available from: 10.1128/JB.186.15.5017-5030.2004
  23. Nesbitt NM, Yang X, Fontán P, Kolesnikova I, Smith I, Sampson NS, et al. A thiolase of Mycobacterium tuberculosis is required for virulence and production of androstenedione and androstadienedione from cholesterol. Infect Immun. 2010;78(1):275–82. Available from: 10.1128/IAI.00893-09
  24. John WG, UK Department of Health Advisory Committee on Diabetes. Use of HbA1c in the diagnosis of diabetes mellitus in the UK. The implementation of World Health Organization guidance 2011. Diabet Med. 2012;29(11):1350–7. Available from: 10.1111/j.1464-5491.2012.03762.x
  25. World Health Organization. Glycated haemoglobin (HbA1c) for the diagnosis of diabetes. Geneva: World Health Organization; 2011.
  26. Gebremicael G, Amare Y, Challa F, Gebreegziabxier A, Medhin G, Wolde M, et al. Lipid Profile in Tuberculosis Patients with and without Human Immunodeficiency Virus Infection. Int J Chronic Dis. 2017;2017:1–7. Available from: 10.1155/2017/3843291
  27. Simonen PP, Gylling HK, Miettinen TA. Diabetes Contributes to Cholesterol Metabolism Regardless of Obesity. Diabetes Care. 2002;25(9):1511–5. Available from: https://doi.org/10.2337/diacare.25.9.1511
  28. Akpovi DC, Gbaguidi LHS, Anago E nie, Affolabi D, Dougnon T gnon V, Faihun F, et al. Tuberculosis treatment raises total cholesterol level and restores high density lipoprotein cholesterol (HDL-C) in patients with pulmonary tuberculosis. African J Biotechnol. 2013;12(41):6019–24. Available from: 10.5897/ajb2013.13073
  29. Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R, Cahyadi AI, Ruslami R. Type 2 Diabetes and its Impact on the Immune System. Curr Diabetes Rev. 2019;15(5):442–9. Available from: 10.2174/1573399815666191024085838
  30. Guerrini V, Prideaux B, Blanc L, Bruiners N, Arrigucci R, Singh S, et al. Storage lipid studies in tuberculosis reveal that foam cell biogenesis is disease-specific. PLoS Pathog. 2018;14(8):1–27. Available from: 10.1371/journal.ppat.1007223
  31. Cui X, Kushiyama A, Yoneda M, Nakatsu Y, Guo Y, Zhang J, et al. Macrophage foam cell formation is augmented in serum from patients with diabetic angiopathy. Diabetes Res Clin Pract. 2010;87(1):57–63. Available from: 10.1016/j.diabres.2009.10.011
  32. Russell DG, Cardona P, Kim M, Allain S. Foamy macrophages and the progression of the human TB granuloma. Natl Inst Heal. 2010;10(9):1–16. Available from: 10.1038/ni.1781.Foamy
  33. Taparia P, Yadav D, Koolwal S, Mishra S. Study of lipid profile in pulmonary tuberculosis patients and relapse cases in relation with disease severity - A pilot study. Int J Sci Appl Res. 2015;2(1):41–50.

How to Cite

Berbudi, A., Camilla, C., Rahmadika, N., Cahyadi, A. I., & Ruslami, R. (2021). Comparison of the nutritional status and lipid profile of tuberculosis patients with and without type 2 diabetes mellitus in primary health care in Bandung. Bali Medical Journal, 10(2), 910–914. https://doi.org/10.15562/bmj.v10i2.2474

HTML
8

Total
21

Share

Search Panel